| 翁娅韵,施政,樊俏玫,黄伟,谢先泽,黄亮.羚羊角治疗儿童热性惊厥的有效性与安全性的系统评价[J].浙江中西医结合杂志,2020,30(3): |
| 羚羊角治疗儿童热性惊厥的有效性与安全性的系统评价 |
| Efficacy and Safety of Prophylactic Lingyangjiao on Prevention of Febrile Seizure in Children: A Systematic Review |
| 投稿时间：2019-11-07 修订日期：2020-02-08 |
| DOI： |
| 中文关键词: 羚羊角 热性惊厥 复发 儿童 系统评价 |
| 英文关键词:Lingyangjiao Febrile seizure Recrudesce Chlidren Systematic Review |
| 基金项目: |
|
| 摘要点击次数: 707 |
| 全文下载次数: 4 |
| 中文摘要: |
| 目的：系统评价羚羊角治疗儿童热性惊厥（FS）的有效性与安全性。方法：计算机检索PubMed、Embase、Cochrance 图书馆、中国生物医学文献数据库、维普网、万方数据库、中国知网自建库至 2019 年 8 月发表的羚羊角联合常规方案治疗儿童 FS 的随机对照试验（RCT）。采用 Cochrane 系统评价手册 5.1.0 进行质量评价，Rev Man 5.3 统计软件进行 Meta 分析。结果：共纳入 9 项研究，合计 753 例患儿。Meta 分析结果示：随访 6 个月羚羊角组与对照组 FS 复发率无统计学差异[ RR =0.58，95% CI（0.30 ~ 1.11），P = 0.10]；随访 12 ~ 24 个月羚羊角组 FS 复发率低于对照组，差异均有统计学意义 [ RR =0.32，95% CI（0.18 ~ 0.55），P ＜0.001]；羚羊角组 FS 平均复发次数低于对照组，差异无统计学意义[ RR =0.53，95% CI（0.25~ 1.12），P =0.10]；羚羊角组与对照组不良反应发生率无统计学差异[RR＝0.71，95％CI（0.43，1.32），P＝0.32]，纳入文献均无严重不良反应报告。结论：对于 FS 患儿，发热时常规治疗基础上口服羚羊角可降低 12 ~ 24 个月 FS 复发率，其安全性与对照组相当。但由于临床研究的方法学质量低，上述结论有待高质量研究进一步验证。 |
| 英文摘要: |
| OBJECTIVE: To systematically evaluate the efficacy and safety of prophylactic Lingyangjiao on the prevention of febrile seizure (FS) in children. METHODS: Retrieved from PubMed, Embase, Cochrane Library, CBM, VIP, Wanfang database and CNKI, randomized controlled trials (RCTs) about use of Lingyangjiao (trial group) versus conventional treatment (control group) to control FS relapse in children up to August 2019. After quality evaluation with Cochrane system evaluation manual 5.1.0, Meta-analysis was performed by Rev Man 5.3 statistical software. RESULTS: A total of 9 RCTs involving 753 patients were included. Meta-analysis showed no significant difference in FS recurrence rate in 6-month follow-up period of Lingyangjiao group compared with the control group [ RR =0.58, 95% CI（0.30 ~ 1.11), P = 0.10]; However, FS relapse rate was markedly decreased at 12-24 months follow-up period [ RR =0.32, 95% CI (0.18 ~ 0.55), P ＜0.001], compared with the control group. There was no statistical significance of recurrent frequency of FS compared with Lingyangjiao group and control group[ RR =0.53, 95% CI（0.25 ~ 1.12），P =0.10]. There was no statistical significance of incidence of adverse reaction in compared with Lingyangjiao group and control group [RR＝0.71, 95％CI (0.43, 1.32), P＝0.32]. CONCLUSIONS: Oral Lingyangjiao during fever can effectively reduce the recurrence rate of FS in 12-24 months for children with FS. The safety of Lingyangjiao is similar to that of control group. However, the evidence remains weak due to the small sample size and poor methodological quality of the included trials. Further, large sample size and well-designed trials are needed. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
